(AP) — Who gets to be first in line for a COVID-19 vaccine? U. S. health authorities hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision. “Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide. “There will be many people who feel that they should have been at the top of the list. ”
Against the backdrop of several pharma companies reporting second-quarter sales declines thanks to COVID-19, AstraZeneca represents a rare exception, thanks to a strong performance by its oncology medicines. But China growth, normally strong, slowed down as Pulmicort tumbled.
SoftBank Group has pulled about $700 million from a Credit Suisse Group fund after executives at the Swiss bank grew concerned that the Japanese conglomerate held conflicting roles in the fund that weren’t fully disclosed to other investors, according to people familiar with the matter.
The race to develop a COVID-19 vaccine is heating up globally and right here in our area. In Seattle, we’ve got a lot of companies and volunteers doing their part to try and help. “It’s been 16 weeks since I had the first dose," said Jennifer Haller of Ballard. "I feel fantastic. " On March 16, Haller, a 43-year-old a tech startup operations manager, became the first person in the country to get injected with the experimental COVID-19 vaccine.
Pharmaceutical company AstraZeneca says it has secured orders for at least 400 million doses of an unproven Covid-19 vaccine that it will be able to start delivering this year. It announced on Thursday that it had “concluded the first agreements” to make the University of Oxford’s potential coronavirus vaccine.
President Trump has launched Operation Warp Speed, which aims to make millions of doses of a coronavirus vaccine available by years end.
The British pharmaceutical giant has agreed to manufacture and distribute an experimental vaccine from the University of Oxford—one of the most advanced candidates—in a partnership aimed at accelerating the widespread availability of the shot if it proves effective.